Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Berz

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Future Oncology (London, England)|October 18, 2025
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancersSara Hurvitz, Matteo Simonelli, Ramón Yarza, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)David Spigel, Robert Jotte, John Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in ChondrosarcomaVivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2016
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and PlasmaKaren L Reckamp, Vladislava O Melnikova, Chris Karlovich, et al.
Cancer Research Communications|January 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or ChemotherapyKai He, David Berz, Shirish M Gadgeel, et al.
Cancer Research Communications|February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced CancersTakeo Fujii, Afsaneh Barzi, Andrea Sartore-Bianchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Future Oncology (London, England)|October 18, 2025
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancersSara Hurvitz, Matteo Simonelli, Ramón Yarza, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2020
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)David Spigel, Robert Jotte, John Nemunaitis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2023
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in ChondrosarcomaVivek Subbiah, Sant P Chawla, Anthony P Conley, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 30, 2016
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and PlasmaKaren L Reckamp, Vladislava O Melnikova, Chris Karlovich, et al.
Cancer Research Communications|January 27, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients With Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2023
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or ChemotherapyKai He, David Berz, Shirish M Gadgeel, et al.
Cancer Research Communications|February 22, 2026
Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid TumorsJong Chul Park, David Berz, Manish R Sharma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of <i>KRAS</i> Mutations in Urine Cell-Free DNA from Patients with Advanced CancersTakeo Fujii, Afsaneh Barzi, Andrea Sartore-Bianchi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.
Pageof 4